Soy protein isolate-polyguluronate nanoparticles loaded with resveratrol for effective treatment of colitis

Li, Wenhao; Bi, Decheng; Jiang, Yi; Yao, Lijun; Cao, Jiang; Yang, Peng; Li, Meiting; Wu, Yan; Xu, Hong; Hu, Zhangli; Xu, Xu

doi:10.1016/j.foodchem.2023.135418

Cited by 20 publications

(4 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, 28 articles were included in this study. Among the excluded articles, 10 focused on the combination of resveratrol with other therapeutic methods as the intervention factor ( Youn et al, 2009 ; Lozano-Pérez et al, 2014 ; Liu et al, 2018 ; Seoane-Viaño et al, 2019 ; Zhang et al, 2019 ; Gandhi et al, 2020 ; Lize et al, 2020 ; Naserifar et al, 2020 ; Pujara et al, 2021 ; Li et al, 2023 ), 1 involved an in vitro experiment ( Sabzevary-Ghahfarokhi et al, 2020 ), 5 primarily studied resveratrol metabolites, derivatives, and precursors ( Larrosa et al, 2010 ; Chen et al, 2017 ; Zhang B. et al, 2022 ; Fei et al, 2022 ; Zhang et al, 2023 ), 3 used modeling techniques to induce other types of intestinal inflammation ( Singh et al, 2012 ; Sun et al, 2020 ; Bilotta et al, 2022 ), and 2 were related to IBD but had different research subjects or purposes ( Wagnerova et al, 2017 ; Lu et al, 2019 ). Among the included studies, 19 were published in English and 9 were in Chinese ( Jun et al, 2010a ; Jun et al, 2010b ; Singh et al, 2012 ; Wagnerova et al, 2017 ; Lu et al, 2019 ; Shenggao et al, 2019 ; Jianheng, 2021 ; Jianheng et al, 2021 ; Qiuping et al, 2021 ).…”

Section: Resultsmentioning

confidence: 99%

“…Therefore, the application of resveratrol using CMC as a carrier for IBD is worth further exploration. Additionally, there have been promising preclinical studies using nano-formulations of resveratrol ( Lozano-Pérez et al, 2014 ; Gandhi et al, 2020 ; Naserifar et al, 2020 ; Pujara et al, 2021 ; Li et al, 2023 ). Although the number of such studies is currently limited, they show potential for addressing the issue of low bioavailability associated with resveratrol.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Resveratrol for inflammatory bowel disease in preclinical studies: a systematic review and meta-analysis

Gu,

Lou,

Zhou

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Inflammatory bowel disease (IBD) is a chronic condition that can be managed with treatment, but it is challenging to get IBD cured. Resveratrol, a non-flavonoid polyphenolic organic compound derived from various plants, has a potential effect on IBD. The current research was set out to investigate the therapeutic effects of resveratrol on animal models of IBD.Methods: A comprehensive search of PubMed, Embase, Web of Science, and Chinese databases was performed. The literature search process was completed independently by two people and reviewed by a third person. The risk of bias in the included literature was assessed using the Collaborative Approach to Meta Analysis and Review of Animal Data from Experimental Stroke (CAMARADES) 10-point quality checklist. The meta-analysis utilized Review Manager 5.4 software to evaluate the efficacy of resveratrol, with histopathological index as the primary outcome measure. Subgroup analysis was conducted based on this indicator. Additionally, meta-analyses were carried out on different outcomes reported in the literature, including final disease activity index, final body weight change, colon length, splenic index, and inflammatory factors.Results: After conducting a thorough literature search and selection process, a total of 28 studies were ultimately included in the analysis. It was found that over half of the selected studies had more than five items with low risk of bias in the bias risk assessment. Relevant datas from included literature indicated that the histopathological index of the resveratrol group was significantly lower than that of the control group (WMD = −2.58 [-3.29, −1.87]). Subgroup analysis revealed that higher doses of resveratrol (>80 mg/kg) had a better efficacy (WMD = −3.47 [-4.97, −1.98]). Furthermore, The data summary and quantitative analysis results of SI and colon length also showed that resveratrol was effective in alleviating intestinal mucosal pathological injury of IBD. In terms of biochemical indicators, the summary analysis revealed that resveratrol affected interleukin-1β (IL-1β), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10), tumor necrosis factor-α (TNF-α), transforming growth factor-β (TGF-β), interferon-γ (IFN-γ), malondialdehyde (MDA), myeloperoxidase (MPO), superoxide dismutase (SOD), and prostaglandin E2 (PGE2) significantly. These effects may be attributed to the mechanism of resveratrol in regulating immune response and inhibiting oxidative stress.Conclusion: This review suggests that resveratrol demonstrated a notable therapeutic impact in preclinical models of IBD, particularly at doses exceeding 80 mg/kg. This efficacy is attributed to the protective mechanisms targeting the intestinal mucosa involved in the pathogenesis of IBD through various pathways. As a result, resveratrol holds promising prospects for potential clinical use in the future.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Resveratrol for inflammatory bowel disease in preclinical studies: a systematic review and meta-analysis

Gu,

Lou,

Zhou

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Finally, 28 articles were included in this study. Among the excluded articles, 10 focused on the combination of resveratrol with other therapeutic methods as the intervention factor (Youn et al, 2009;Lozano-Pérez et al, 2014;Liu et al, 2018;Seoane-Viaño et al, 2019;Zhang et al, 2019;Gandhi et al, 2020;Lize et al, 2020;Naserifar et al, 2020;Pujara et al, 2021;Li et al, 2023), 1 involved an in vitro experiment (Sabzevary-Ghahfarokhi et al, 2020), 5 primarily studied resveratrol metabolites, derivatives, and precursors (Larrosa et al, 2010;Chen et al, 2017;Zhang B. et al, 2022;Fei et al, 2022;Zhang et al, 2023), 3 used modeling techniques to induce other types of intestinal inflammation (Singh et al, 2012;Sun et al, 2020;Bilotta et al, 2022), and 2 were related to IBD but had different research subjects or purposes (Wagnerova et al, 2017;Lu et al, 2019). Among the included studies, 19 were published in English and 9 were in Chinese (Jun et al, 2010a;Jun et al, 2010b;Singh et al, 2012;Wagnerova et al, 2017;Lu et al, 2019;Shenggao et al, 2019;Jianheng, 2021;Jianheng et al, 2021;Qiuping et al, 2021).…”

Section: Description Of the Included Studiesmentioning

confidence: 99%

“…Therefore, the application of resveratrol using CMC as a carrier for IBD is worth further exploration. Additionally, there have been promising preclinical studies using nano-formulations of resveratrol (Lozano-Pérez et al, 2014;Gandhi et al, 2020;Naserifar et al, 2020;Pujara et al, 2021;Li et al, 2023). Although the number of such studies is currently limited, they show potential for addressing the issue of low bioavailability…”

Section: Dose and Formulation Of Resveratrol For Ibdmentioning

confidence: 99%

DataSheet1.docx

View full text Add to dashboard Cite

Fabrication and Characterization of Resveratrol-Loaded Gliadin Particles Stabilized by Gelatin

Zhao

Xiong

et al. 2023

Food Biophysics

View full text Add to dashboard Cite

Soy protein isolate-polyguluronate nanoparticles loaded with resveratrol for effective treatment of colitis

Cited by 20 publications

References 35 publications

Resveratrol for inflammatory bowel disease in preclinical studies: a systematic review and meta-analysis

Resveratrol for inflammatory bowel disease in preclinical studies: a systematic review and meta-analysis

DataSheet1.docx

Fabrication and Characterization of Resveratrol-Loaded Gliadin Particles Stabilized by Gelatin

Contact Info

Product

Resources

About